All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

SALVAT receives FDA approval for clotic targeting fungal infections for otomycosis with orphan drug designation
Small molecule, infectious disease, antifungal, otomycosis, orphan drug designation - Read more

THE GOOD
Business Development & Partnerships

Kite Pharma, Pregene partner on in vivo CAR-T development worth up to $1.64B
Research collaboration, oncology, cell therapy, milestone payments, global - Read more

Dianthus Therapeutics, Nanjing Leads Biolabs partner on autoimmune bispecific antibody, $1B potential deal value
Licensing deal, autoimmune, antibody, milestone payments - Read more

AstraZeneca, Immunai partner on AI-driven IBD target discovery worth $85M
Research collaboration, autoimmune, AI/ML, milestone payments - Read more

Sanofi, EVOQ partner on NanoDisc autoimmune platform in $500M deal
Research collaboration, autoimmune, milestone payments, global - Read more

ME Therapeutics, National Research Council of Canada license CD22 nanobody for CAR therapy development
Licensing deal, oncology, cell therapy, nanobody technology - Read more

Taiho Pharma licenses Haihe's PI3Kα inhibitor risovalisib for Japan commercialization
Licensing deal, oncology, small molecule, milestone payments, rare disease - Read more

Jacobio Pharma, Oceanpine Capital partner; Oceanpine acquires 80% Jacoray equity for RMB 200M ($28M)
Equity investment, oncology, small molecule, milestone payments - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps = Fast Deployment + Lower Cost

We've built 100+ pharma sales teams for companies of all sizes, and we can help you.

We build agile field teams that scale based on your needs - all with fast deployment + lower cost than full-time reps.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

Merck & Co.'s Keytruda shows overall survival benefit in Ph3 trial for platinum-resistant recurrent ovarian cancer
Antibody, cancer, immune checkpoint inhibitor, ovarian cancer, PD-1, combination therapy - Read more

Praxis reports positive Ph3 results for ulixacaltamide targeting T-type calcium channels in essential tremor, plans FDA filing
Small molecule, neurological, calcium channel blocker, essential tremor - Read more

Johnson & Johnson's Tecvayli-Darzalex combination meets Ph3 endpoints in earlier-line multiple myeloma, halting trial early
Antibody, cancer, monoclonal antibody, multiple myeloma, combination therapy, BCMA target - Read more

Novartis Fabhalta shows kidney function benefits in Ph3 IgA nephropathy trial, eyes full FDA approval
Small molecule, kidney disease, complement inhibitor, IgA nephropathy, rare disease - Read more

Aicuris prepares FDA filing for Pritelivir targeting helicase-primase after Ph3 success in herpes simplex virus
Small molecule, infectious disease, helicase primase inhibitor, herpes simplex virus, immunocompromised patients - Read more

THE GOOD
Fundraises

Adcytherix raises $122M Series A, antibody drug conjugates targeting cancer
Antibody drug conjugate, oncology, clinical-stage, platform technology - Read more

Veradermics raises $150M Series C, advancing hair regrowth pill through regulatory submissions
Hair regrowth, small molecule, clinical-stage, extended-release formulation - Read more

BridGene Biosciences raises $28M Series B+, advancing TEAD inhibitor BGC-515 clinical development
Small molecule, oncology, autoimmune, platform technology, clinical-stage - Read more

Peptilogics raises $78M Series B for prosthetic joint infection treatment program
Infectious disease, clinical-stage, prosthetic joint infection, antimicrobial - Read more [Paywall]

C4 Therapeutics raises $125M public offering, advancing targeted protein degradation science
Clinical-stage, targeted protein degradation, platform technology, biopharmaceutical - Read more

THE GOOD
Investments

Next Gen Diagnostics relocates lab to Kendall Square to expand genomics-based infection tracking capabilities
Genomic sequencing, infectious disease, operational, strategic - Read more

THE GOOD
Politics & Policy

California Governor Newsom signs laws restricting PBM practices, banning spread pricing and pharmacy steering
Regulatory, operational, financial, strategic - Read more

THE GOOD
Product Launches

Genentech launches direct-to-consumer program offering Xofluza flu treatment at 70% discount for flu season
Small molecule, infectious disease, strategic, operational, cost reduction - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Regulatory

FDA orphan drug Director Sandra Retzky departs amid staffing shuffle under Kennedy leadership
Orphan drugs, rare disease, regulatory, operational - Read more

THE BAD
Strategic Plans

Kezar Life Sciences initiates strategic review after FDA clash delays zetomipzomib autoimmune hepatitis program by two years
Immunoproteasome inhibitor, autoimmune, regulatory, strategic, operational - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here